Ca2+ channels and excitation-contraction coupling.
Ashcroft
F M
FM
University Laboratory of Physiology, Oxford, UK.
D000200:Action Potentials; D000818:Animals; D016466:CHO Cells / Q000378:metabolism; D002110:Caffeine / Q000494:pharmacology; D002118:Calcium / Q000502:physiology*; D015220:Calcium Channels / Q000187:drug effects / Q000235:genetics / Q000502:physiology*; D006224:Cricetinae; D004095:Dihydropyridines / Q000494:pharmacology; D005796:Genes; D006801:Humans; D008305:Malignant Hyperthermia / Q000503:physiopathology; D008322:Mammals / Q000378:metabolism; D051379:Mice; D008817:Mice, Mutant Strains; D009119:Muscle Contraction / Q000502:physiology*; D009124:Muscle Proteins / Q000235:genetics / Q000502:physiology; D009135:Muscular Diseases / Q000235:genetics; D009200:Myocardial Contraction / Q000502:physiology; D009928:Organ Specificity; D015202:Protein Engineering; D011978:Receptors, Nicotinic / Q000187:drug effects / Q000235:genetics / Q000502:physiology*; D012433:Ryanodine / Q000494:pharmacology; D019837:Ryanodine Receptor Calcium Release Channel; D012519:Sarcoplasmic Reticulum / Q000378:metabolism; D015398:Signal Transduction
D015220:Calcium Channels; D004095:Dihydropyridines; D009124:Muscle Proteins; D011978:Receptors, Nicotinic; D019837:Ryanodine Receptor Calcium Release Channel; D012433:Ryanodine; D002110:Caffeine; C038806:1,4-dihydropyridine; D002118:Calcium